Management of liver cancer. The Surgeon's point of view

Rabinel, P.; Dousse, Damien; Muscari, Fabrice; Suc, B.

doi:10.1016/j.rpor.2017.02.001

Cited by 17 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although outstanding advances in surgical techniques and radio-chemotherapy regimens have been achieved in recent decades, the prognosis for most patients with HCC remains poor. Therefore, novel therapeutic strategies are needed to treat HCC more effectively ( 3 , 4 , 6 ).…”

Section: Discussionmentioning

confidence: 99%

“…Liver cancer is one of the most common malignancies worldwide, with an increasing incidence, especially in China ( 1 – 3 ). Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer; it is estimated to be the second leading cause of cancer-related death in developing countries and the sixth leading cause in developed countries ( 4 – 6 ). Despite recent advances in HCC management, including surgical resection, radiofrequency ablation, liver transplantation, and transcatheter arterial chemoembolization (TACE), the prognosis of most HCC patients remains poor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism

2018

View full text Add to dashboard Cite

MicroRNAs (miRs) have been proposed as minimally invasive prognostic markers for various types of cancer, including liver cancer, which is one of the most common cancers worldwide. In the present study, the expression of miR-34a in human liver cancer tissues and cell lines was evaluated and the effects of miR-34a on cell proliferation, invasion and glycolysis in hepatocellular carcinoma (HCC) cells were determined. The results indicated that miR-34a was downregulated in human liver cancer tissues. Overexpression of miR-34a significantly inhibited liver cancer cell proliferation and clone formation. In terms of the underlying mechanism, miR-34a was indicated to negatively regulate the expression of lactate dehydrogenase A (LDHA), which consequently inhibited LDHA-dependent glucose uptake in the cancer cells, as well as cell proliferation and invasion. Collectively, these data suggest that miR-34a functions as a negative regulator of glucose metabolism and may serve as a novel marker for liver cancer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism

2018

View full text Add to dashboard Cite

show abstract

“…Moreover, the recurrence rate of liver cancer following surgery is high equal to 70-80% (16,13). Various types of treatment have been used for liver cancer, including surgical resection and chemotherapy (51).…”

Section: Introductionmentioning

confidence: 99%

Enhancing the Efficacy of Albendazole for Liver Cancer Treatment Using Mesoporous Silica Nanoparticles: An In Vitro Study

Ghaferi

Zahra

Shahmabadi

et al. 2021

Preprint

View full text Add to dashboard Cite

The present study aimed to synthesize albendazole (ABZ)-loaded Mobil Composition of Matter No. 41 (MCM-41) nanoparticles (NPs) to increase the efficacy of the drug against liver cancer. ABZ was loaded into MCM-41 NPs, and after in vitro characterization, such as size, size distribution, zeta potential, morphology, chemical composition, thermal profile, drug release, surface and pore volume, and pore size, their biological effects were evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) cell migration assays. The results demonstrated that monodispersed and spherical NPs with a size of 220 ± 11.5 and 293 ± 8.7 nm, for MCM-41 NPs and ABZ-loaded MCM-41 NPs, respectively, and drug loading efficiency of 30% were synthesized. ABZ was loaded physically into MCM-41 NPs, leading to a decrease in surface volume, pore size, and pore volume. Also, MCM-41 NPs could increase the cytotoxicity effects of ABZ by 2.9-fold (IC50 = 23 and 7.9 µM for ABZ and ABZ-loaded MCM-41 NPs, respectively). In addition, ABZ-loaded MCM-41 NPs, compared to that of ABZ, caused a significant decrease in cell migration. Overall, the results of the present study suggest evaluating the potency of MCM-41 NPs, as a potent nanoplatform, for ABZ delivery in vivo environment.

show abstract

“…Nowadays, partial hepatectomy (PHx) is the only option offering potential cure for patients with CRCLM 9 , 10 . Regardless of advances in this field, less than 20% of patients are eligible for PHx 11 .…”

Section: Introductionmentioning

confidence: 99%

Partial hepatectomy enhances the growth of CC531 rat colorectal cancer cells both in vitro and in vivo

Parte

González-Arribas

Diaz-Sanz

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Partial hepatectomy (PHx) is the gold standard for the treatment of colorectal cancer liver metastases. However, after removing a substantial amount of hepatic tissue, growth factors are released to induce liver regeneration, which may promote the proliferation of liver micrometastases or circulating tumour cells still present in the patient. The aim of this study is to assess the effect of PHx on the growth of liver metastases induced by intrasplenic cell inoculation as well as on in vitro proliferation of the same cancer cell line. Liver tumours were induced in 18 WAG/RijHsd male rats, by seeding 250,000 syngeneic colorectal cancer cells (CC531) into the spleen. The left lateral lobe of the liver was mobilized and in half of the animals it was removed to achieve a 40% hepatectomy. Twenty-eight days after tumour induction, the animals were sacrificed and the liver was removed and sliced to assess the relative tumour surface area (RTSA%). CC531 cells were cultured in presence of foetal calf serum, non-hepatectomised (NRS) or hepatectomized rat serum (HRS), and their proliferation rate at 24, 48, and 72 h was measured. RTSA% was significantly higher in animals which had undergone PHx than in the controls (non-hepatectomised) (46.98 ± 8.76% vs. 18.73 ± 5.65%; p < 0.05). Analysing each lobe separately, this difference in favour of hepatectomized animals was relevant and statistically significant in the paramedian and caudate lobes. But in the right lobe the difference was scarce and not significant. In vitro, 2.5% HRS achieved stronger proliferative rates than the control cultures (10% FCS) or their equivalent of NRS. In this experimental model, a parallelism has been shown between the effect of PHx on the growth of colorectal cancer cells in the liver and the effect of the serum on those cells in vitro.

show abstract

Management of liver cancer. The Surgeon's point of view

Cited by 17 publications

References 34 publications

MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism

MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism

Enhancing the Efficacy of Albendazole for Liver Cancer Treatment Using Mesoporous Silica Nanoparticles: An In Vitro Study

Partial hepatectomy enhances the growth of CC531 rat colorectal cancer cells both in vitro and in vivo

Contact Info

Product

Resources

About